Monzon JG - Search Results

1

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.

Muniz TP, Araujo DV, Savage KJ, Cheng T, Saha M, Song X, Gill S, Monzon JG, Grenier D, Genta S, Allen MJ, Arteaga DP, Saibil SD, Butler MO, Spreafico A, Hogg D. Muniz TP, et al. Among authors: monzon jg. Cancers (Basel). 2021 Dec 24;14(1):89. doi: 10.3390/cancers14010089. Cancers (Basel). 2021. PMID: 35008256 Free PMC article.

2

NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer.

Kennecke HF, Auer R, Cho M, Dasari NA, Davies-Venn C, Eng C, Dorth J, Garcia-Aguilar J, George M, Goodman KA, Kreppel L, Meyer JE, Monzon J, Saltz L, Schrag D, Smith JJ, Zell JA, Das P; National Cancer Institute Rectal-Anal Task Force. Kennecke HF, et al. J Natl Cancer Inst. 2023 Dec 6;115(12):1457-1464. doi: 10.1093/jnci/djad143. J Natl Cancer Inst. 2023. PMID: 37535679 Free PMC article.

3

Absence of the L37P polymorphism in exon 1 of the CDKN2A gene.

Fung JJ, Liu L, Gao L, Monzon J, Lassam NJ, Hogg D. Fung JJ, et al. Mol Cell Probes. 1997 Jun;11(3):231-2. doi: 10.1006/mcpr.1997.0098. Mol Cell Probes. 1997. PMID: 9232623 No abstract available.

4

Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma.

Hogg D, Brill H, Liu L, Monzon J, Summers A, From L, Lassam NJ. Hogg D, et al. J Cutan Med Surg. 1998 Jan;2(3):172-9. doi: 10.1177/120347549800200312. J Cutan Med Surg. 1998. PMID: 9479083 Review.

5

CDKN2A mutations in multiple primary melanomas.

Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. Monzon J, et al. N Engl J Med. 1998 Mar 26;338(13):879-87. doi: 10.1056/NEJM199803263381305. N Engl J Med. 1998. PMID: 9516223 Free article.

6

Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.

Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D. Liu L, et al. Nat Genet. 1999 Jan;21(1):128-32. doi: 10.1038/5082. Nat Genet. 1999. PMID: 9916806

7

A phase 2 study of tremelimumab in patients with advanced uveal melanoma.

Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. Joshua AM, et al. Among authors: monzon jg. Melanoma Res. 2015 Aug;25(4):342-7. doi: 10.1097/CMR.0000000000000175. Melanoma Res. 2015. PMID: 26050146 Clinical Trial.

8

Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.

Suo A, Chan Y, Beaulieu C, Kong S, Cheung WY, Monzon JG, Smylie M, Walker J, Morris D, Cheng T. Suo A, et al. Among authors: monzon jg. Oncologist. 2020 May;25(5):438-446. doi: 10.1634/theoncologist.2019-0674. Epub 2020 Feb 12. Oncologist. 2020. PMID: 32048768 Free PMC article.

9

Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma.

Hogg D, Monzon JG, Ernst S, Song X, McWhirter E, Savage KJ, Skinn B, Romeyer F, Smylie M. Hogg D, et al. Among authors: monzon jg. Curr Oncol. 2020 Aug;27(4):204-214. doi: 10.3747/co.27.5985. Epub 2020 Aug 1. Curr Oncol. 2020. PMID: 32905202 Free PMC article.

10

Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis.

Rigo R, Doherty J, Koczka K, Kong S, Ding PQ, Cheng T, Cheung WY, Monzon JG. Rigo R, et al. Among authors: monzon jg. Curr Oncol. 2021 Oct 5;28(5):3978-3986. doi: 10.3390/curroncol28050338. Curr Oncol. 2021. PMID: 34677256 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters